β-Nicotinamide mononucleotide

SKU: orb1302620

Description

β-Nicotinamide mononucleotide (NMN) is a key biosynthetic precursor to the essential coenzyme NAD+. It is widely used in research to study cellular metabolism, aging, and age-related diseases in both in vitro and in vivo experimental models.

Research Area

Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1094-61-7
• MW: 334.22
• Purity: >99.99% (May vary between batches)
• Formula: C₁₁H₁₅N₂O₈P
• SMILES: NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)([O-])=O)[C@@H](O)[C@H]1O
• Target: Endogenous Metabolite
• Solubility: DMSO:Insoluble;H2O:85.8 mg/mL (256.72 mM)

Bioactivity

• In Vivo:
  METHODS: To study the effects on aging, β-nicotinamide mononucleotide (100-300 mg/kg) was administered in drinking water to normally aging wild-type C57BL/6N mice. The administration began at 5 months of age and continued for 12 months until the mice were 17 months old. RESULTS: β-nicotinamide mononucleotide effectively attenuated age-related physiological decline in mice. β-nicotinamide mononucleotide did not have any significant toxic or deleterious effects, inhibited age-related weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and lipid levels, and improved insulin resistance. sensitivity and lipid levels, and improved eye function and other pathophysiology.
  Read more...
• In Vitro:
  METHODS: Human corneal epithelial cells HCECs were treated with glucose (25 mM) and β-nicotinamide mononucleotide (5-1000 µM) for 48 h. Cell viability was measured by Trypan blue staining. RESULTS: The effects of different concentrations of β-nicotinamide mononucleotide on HCEC damage induced by high glucose were analyzed. 125, 250 and 500 µM β-nicotinamide mononucleotide showed significant protective effects. METHODS: Late passaged MSCs LP MSCs were treated with β-nicotinamide mononucleotide (100 µM) for 24 h and mitochondrial morphology was analyzed. RESULTS: The mitochondrial staining in LP-MSCs was more diffuse and less intense, while the distribution of mitochondria became concentrated after β-nicotinamide mononucleotide treatment. β-nicotinamide mononucleotide treatment could effectively normalize the mitochondrial morphology and improve the function of mitochondria in senescent MSCs.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

βNicotinamide mononucleotide, β-Nicotinamide mononucleotide, β-NM, β Nicotinamide mononucleotide, Alzheimer's, b-Nicotinamide mononucleotide, b-NM, beta-Nicotinamide mononucleotide, beta-NM, cardioprotection, cancer, Endogenous Metabolite, disease, diabetes, inhibit, intermediate, NAD, NMN, obesity, EndogenousMetabolite, Inhibitor

Compound Identifiers

PubChem CID

14180